Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyclosporine + Eltrombopag/Hetrombopag + Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia/ Severe Aplastic Anemia

NCT07558434 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07558434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07558434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyclosporine + Eltrombopag/Hetrombopag + Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia/ Severe Aplastic Anemia
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2029
Enrollment
43 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

severe aplastic anemia (saa), transfusion-dependent non-severe aplastic anemia